Clinical Trial

Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a open-Label, dose-escalation study to evaluate the safety, tolerability and antitumor activity of DIT309 in subjects with advanced bone and soft tissue sarcomas.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-26.
Status change: Not Yet Recruiting → Recruiting 2026-04-29
Trial Details
NCT Number NCT07052383
Lead Sponsor Tcelltech Inc.
Collaborators: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions Osteosarcoma, Soft Tissue Sarcoma
Enrollment 15 participants
Start Date 2025-11-06
Primary Completion 2027-10-10 (estimated)
Study Completion 2027-10-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-05